Trogenix

Focus: Trogenix is an early-stage UK-based biotechnology company founded in 2023, specializing in viral immunotherapy for oncology. The company is publicly listed but has not yet commercialized products.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Trogenix

AI assessmentNot Hiring

No open roles listed right now. Follow Trogenix to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

TGX-007

Glioblastoma (GBM)

PHASE_1_2

Clinical Trials (1)

NCT07346144Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Phase 1/2

Help build intelligence for Trogenix

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly public biotech company with a novel viral immunotherapy platform in high-need oncology space
Early-stage career acceleration potential with greater individual impact and equity upside typical of pre-revenue stage companies
Located in Edinburgh, UK with access to strong academic research ecosystem and European biotech talent pool

Watch Out For

Single program in Phase 1/2 (TGX-007) represents very early-stage pipeline with significant attrition risk and uncertain timelines to value creation
No current job openings and minimal operating history (founded 2023) suggest limited hiring and organizational scaling questions
Missing critical financial data (funding, revenue, cash position) creates visibility gap on runway and sustainability of operations

Generated by Claude from Trogenix's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 1 clinical trial

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline